Skip to main
FULC

FULC Stock Forecast & Price Target

FULC Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 22%
Hold 56%
Sell 22%
Strong Sell 0%

Bulls say

Fulcrum Therapeutics is facing various risks, such as unexpected clinical or regulatory issues, potential commercial setbacks, and dilutive financing, which could negatively impact the stock. However, there is potential for upside from strategic alternative plans or regulatory flexibility. The company recently discontinued its product candidate, pociredir, due to concerns over its class of drugs, but still has a strong cash position of $333 million. Due to these uncertainties, the rating for the stock has been downgraded to Underweight and the price target has been reduced from $23 to $3, removing all value for pociredir in the projected mid-2027.

Bears say

Fulcrum Therapeutics is in a dire situation after the FDA discontinued their flagship product Pociredir's development for the treatment of sickle cell disease. The FDA's concerns about the potential risks of the drug's class, compounded by recent data from a similar drug, have led to a halt in the company's development plans. This has led to a significant loss of potential value for Fulcrum and raises concerns about their ability to secure additional capital, making it prudent for investors to stay away until further updates are announced.

FULC has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 22% recommend Buy, 56% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fulcrum Therapeutics Inc (FULC) Forecast

Analysts have given FULC a Hold based on their latest research and market trends.

According to 9 analysts, FULC has a Hold consensus rating as of Sep 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fulcrum Therapeutics Inc (FULC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.